PDA Letter Article

Expand Your Network and Have Fun!

by Rebecca Stauffer, PDA

Conference
 

Schedule of Networking Events at the 2019 PDA Annual Meeting

Monday, March 11

PDA Charity Walk/Run for Global Genes®

Put on your walking or running shoes in the morning before the 2019 PDA Annual Meeting comments to support Global Genes®, a nonprofit advocating for patients with rare diseases. Meet behind the hotel for a scenic 5k run/3k walk along San Diego’s Embarcadero seaside walkway. Meet at 6 a.m. $45 per participant.

PDA Orientation Lunch

Are you a new PDA member? Or are you a young professional? Is this your first time attending the Annual Meeting? If you answered "yes" to any of these questions, join your peers for a networking lunch. 11:30 a.m.–12:30 p.m. (invitation only)

Exhibit Hall Grand Opening Reception

Join fellow attendees for the opening of the Exhibit Hall. Refreshments will be provided. 5–6 p.m.

Tuesday, March 12

Nautical Nights Reception

Anchors aweigh! Celebrate a successful two days with food, drinks and entertainment at the Marina Terrace. 6:30–9:30 p.m. Included with main conference registration. Guest tickets can be purchased for $70.

Workforce of the Future

This year, the Annual Meeting includes a special breakout session featuring presentations from young professionals.

Wednesday, March 13

10:45 a.m.–11:15 a.m.

“Capture and Reuse of Critical Knowledge during Technology Transfer”

Paige E. Kane, PhD, Director, Knowledge Management, Merck & Co., Inc.

Martin J. Lipa, Executive Director, Knowledge Management, Merck & Co., Inc.

11:15 a.m.–11:30 a.m.

“Considerations and Proof of Concept Data for the Development of a Next-Generation Sequencing Method for Adventitious Virus Detection”

Maria M. Bednar, Scientist I, AT Virology, Biogen

11:30 a.m.–11:45 a.m.

“Antisense Oligonucleotide Therapies: Molecule Requirements from a Packaging Perspective”

Amy A. Kim, Analyst-Specialist, West Pharmaceutical Services, Inc.

Session Moderators: Jason Kerr, Quality Assurance Specialist, Amgen and Kristin Valente, Director, Vaccine Process Development & Commercialization, Downstream, Merck & Co. Inc.